POSTER PRESENTATIONS
|
|
- Augusta Wells
- 5 years ago
- Views:
Transcription
1 POSTER PRESENTATIONS The following are summaries of posters presented at the American Psychiatric Association Annual Meeting held in Philadelphia, Pennsylvania, May 18-23, 2002 DOES STIMULANT THERAPY FOR ATTENTION- DEFICIT/ HYPERACTIVITY DISORDER BEGET LATER SUBSTANCE ABUSE? A META-ANALYTIC REVIEW OF THE LITERATURE Wilens T, Faraone S, Biederman J, Gunawardene S, Prince J Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. A team of investigators at the Clinical Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School have conducted a meta-analysis of the medical literature in order to quantify the relationship between stimulant therapy and subsequent substance use disorders (SUDs) in attention-deficit/hyperactivity disorder (ADHD) youth. Their objective was to review cumulative findings regarding the putative association between prior exposure to stimulants and SUD. With the support of a grant from the US Public Health Service, the investigators undertook a review of 5 studies, including 2 with follow-up in adolescence and 3 in young adulthood, comprising 576 medicated subjects and 339 unmedicated subjects who were followed for at least 4 years. 1-5 They reported the following odds ratios (listed as protective effect of stimulant therapy) and 95% confidence intervals (CI) for the studies by meta-analysis: These findings suggest that stimulants have a protective effect against SUD, with 7 of the odds ratios (from 4 studies) being >1.0; 5 of these odds ratios are statistically significant. Two of the odds ratios (from 1 study) are <1, suggesting an adverse impact of stimulants, but these are not statistically significant. The pooled estimate of the odds ratio from the meta-analysis was 2.3, and was statistically significant (z = 2.3; P =.02; 95% CI for odds ratio: 1.1, 4.6). This odds ratio indicates a 2.3-fold reduction in risk for SUD in youth who are treated pharmacologically, compared with youth not receiving pharmacotherapy for ADHD. The study design effect indicated that studies of treated and untreated youth with ADHD who had similar baseline severity resulted in larger odds ratios (ORs) than studies that had dissimilar baseline severity. As a group, the data from studies that had similar baseline severity showed a statistically significant protective effect (OR = 3.5 [2.2, 5.8]). The 2 data points from the 1 study that did not have similar baseline severity between treatment groups both suggest that stimulants increased the risk of SUD outcomes (OR = 0.5 [0.34, 0.88]). The study had a number of limitations in that it included a small number of overall studies (N = 5), some published and others only presented, including a total of 915 subjects who were predominantly male. Moreover, the naturalistic, nonrandomized nature of these studies may have created confounds (eg, severity of illness, comorbidity, family history of SUD) that may have independently affected outcome. Although the subject of inquiry was the effect of stimulant therapy on SUD, 4% of all study subjects were taking other medications. In addition, the duration and adequacy of treatment were not delineated; definitions of substance abuse or dependence varied from study to study; and SUD outcomes were determined by subjective reports of patients or parents. Despite these limitations, this meta-analysis indicates that the pharmacotherapy of ADHD does not increase the risk for subsequent SUD. In contrast, the available Advanced Studies in Medicine 925
2 data suggest that stimulant medication has a protective effect on later SUD. Of special note are the investigators findings of a less robust protective effect of stimulant treatment in reducing SUD in adulthood (1.6 fold relative to adolescence [5.8 fold]). An important finding for child psychiatry is the fact that stimulants offer a protective effect against SUD in youth with ADHD. However, further study is needed to investigate the long-term SUD outcome and putative mechanisms of reduced SUD risk in male and female youth with ADHD who are treated pharmacologically. REFERENCES 1. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-adhd participants. J Learn Disabil. 1999;31(6): Biederman J, Wilens T, Mick E, Spencer T, Faraone S. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):20; 3. Wilens T, Biederman J, Mick E, Spencer T. Pharmacotherapy reduces substance use disorders in ADHD in midadolescence. Paper presented at: College of Problems with Drug Dependence, 1999; Acapulco, Mexico. 4. Molina B, Pelham W, Roth J. Alcohol and other substance use and abuse in ADHD adolescents: patterns of use compared to controls and prediction from childhood. Paper presented at: International Society for Research in Child and Adolescent Psychiatry; 1999; Barcelona, Spain. 5. Huss M. ADHD and substance abuse. Paper presented at: IX Annual European Congress of Psychiatry; 1999; Hamburg, Germany. PTSD AND ADHD: COMORBIDITY, SYMPTOM OVERLAP, AND SIGNIFICANCE OF AGE AT FIRST TRAUMA Irene Powch, PhD Portland VA Medical Center and Oregon Health Sciences University The child literature reports significantly higher rates of attention-deficit/hyperactivity disorder (ADHD) in traumatized populations 1 and traumatized populations with posttraumatic stress disorder (PTSD) than in controls. 2,3 There is evidence that early trauma may cause neurobiological changes that could manifest as hyperactivity in the context of limbic dysregulation. 4 There are no published studies on trauma history or PTSD comorbidity with ADHD in adults. It is not known whether adults with a history of trauma before 8 years of age report greater hyperactivity and childhood ADHD that persisted into late adulthood than those who were not traumatized until later in life. These unanswered questions relating to the relationship between PTSD and ADHD have gained particular relevance in our post-september 11 society, as large numbers of Americans, adults and children, are reporting PTSD symptomology. This suggests the possibility of a surge in ADHD in the years ahead. The purpose of the present study was to provide preliminary evidence in support of hypotheses that implicate early trauma in the etiology of ADHD. The hypotheses of the study were: Veterans who experienced early trauma (before 8 years of age) will evidence higher rates of hyperactivity present since childhood than veterans who first experienced trauma later in life; Childhood physical abuse (which, it could be argued, might be provoked by the hyperactive child) would not be more strongly associated with hyperactivity than childhood sexual abuse (which is less readily explained as being provoked by the child); Childhood hyperactivity will not be associated with greater exposure to subsequent trauma as measured by combat exposure and total traumatic life event exposure over the lifetime. The investigator also assumed that a different pattern of symptoms would be associated with childhood abuse than with combat trauma, and hyperactivity would be associated more often with childhood abuse. Investigators recruited veterans from outpatient mental health and domiciliary services at a Veterans Administration hospital. PTSD was diagnosed with the Clinician Administered PTSD Scale; ADHD was diagnosed with a structured clinical interview created to assess Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) ADHD symptoms in early childhood (to third grade) and in the present. Subjects also completed 5 other measures of trauma history, PTSD, and ADHD. The remaining 46 study subjects were aged 30 to 56 years. Nearly half (44%) of the subjects reported an experience of childhood trau- 926 Vol. 2, No. 25 November 2002
3 ma, and nearly half (47%) reported moderate to extreme combat exposure. Investigators found that subjects who experienced child physical abuse were not more inclined toward hyperactivity than those who experienced sexual abuse. In fact, the multiple regression beta weight between child sexual abuse and hyperactivity was higher than that between child physical abuse and hyperactivity (.35; P<.05 vs a nonsignificant.13). Table 1 summarizes the trauma histories and psychiatric diagnoses for this sample. Table 2 indicates that subjects who experienced trauma early in life reported a significantly greater number of ADHD symptoms across the lifespan (18.5 symptoms vs 12.8 symptoms; P<.05). They also reported significant elevations in current depression, anxious arousal, dissociation, and anger/irritability compared with those who were first traumatized later in life. Childhood hyperactivity was not found to predispose the subjects in this sample to more combat exposure (r = -.24) or to a greater number of traumatic life events (r =.19), both nonsignificant correlations. Combat exposure and traumatic life events were, however, significantly correlated with a current diagnosis of PTSD (r =.40; P<.01, and r =.34; P<.05, respectively). ADHD symptoms appear to be a more persistent sequela of childhood sexual abuse than PTSD symptoms (r =.32; P<.05 vs a nonsignificant r = -.01). In addition, the patterns of correlations between PTSD symptoms and ADHD symptoms found in this study provide a compelling argument to seriously consider trauma in the etiology of at least some subtypes of ADHD. Opportunities for future research in this area abound, including replication of the study presented here with other adult populations. Moreover, a longitudinal study could more definitively address questions of causation (Does trauma increase the risk of developing ADHD, or does ADHD increase the risk of exposure to trauma in early childhood?), as well as questions of remission rates (Is ADHD a more persistent consequence of early trauma than is PTSD?). Another area for investigation is whether patients with trauma-induced ADHD experience a differential treatment response than do those with other subtypes of ADHD. In addition, experimental cognitive testing techniques may be applied to ascertain the role of different types of impulsivity among early trauma sur- Table 1.Trauma Histories and Psychiatric Diagnoses in Study Sample* History/Diagnosis Percentage Affected First trauma before 8 years of age (average age 6 years) 44% First trauma after 8 years of age (average age 18 years) 56% Physically abused moderately to extremely 44% Sexually abused moderately to extremely 40% Combat exposure moderate to extreme 47% Current PTSD diagnosis 70% Current ADHD diagnosis 13% ADHD diagnosis in childhood, but not current 24% Childhood hyperactivity 30% Childhood inattention 33% Current hyperactivity 15% Current inattention 48% *N = 46. PTSD = post-traumatic stress disorder; ADHD = attention-deficit/ hyperactivity disorder. Table 2. Symptom Severity Depending on Age of First Trauma* Early Trauma Late Trauma (n = 20) (n = 22) ADHD total (child and adult) Child hyperactivity Child inattention Adult hyperactivity Adult inattention Anxious arousal (TSI) Depression (TSI) Dissociation (TSI) Anger/irritability (TSI) Tension-reduction behavior (TSI) Lifetime traumatic events exposure *Analysis of variance (ANOVA) was used to compare means. P<.05; P<.005. ADHD = attention-deficit/hyperactivity disorder; TSI = test for severe impairment. Advanced Studies in Medicine 927
4 vivors with ADHD, without ADHD, and those with ADHD and no history of trauma. REFERENCES 1. Putnam FW. Developmental pathways following sexual abuse. Paper presented at: The Annual Meeting of the Society for Adolescent Psychiatry; 1994; San Francisco, Ca. 2. Famularo R, Fenton T, Kinscherff R, et al. Psychiatric comorbidity in childhood post traumatic stress disorder. Child Abuse Negl. 1996;20: Glod CA, Teicher MH. Relationship between early abuse, posttraumatic stress disorder, and activity levels in prepubertal children. J Am Acad Child Adolesc Psychiatry. 1996;35: Yutaka I, Teicher MN, Glod CA, et al. Increased prevalence of electrophysiological abnormalities in children with psychological, physical, and sexual abuse. J Neuropsychiatry Clin Neurosci. 1993;5: EFFICACY OF ATOMOXETINE IN CHILDREN AND ADOLESCENTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER Brown WJ, Wernicke J, Allen AJ, Michelson D, Harder D, Milton D, Kelsey D Eli Lilly and Company, Indianapolis, Indiana A poster presented at the 2002 American Psychiatric Association APA Annual Meeting demonstrates promising results for the investigational drug atomoxetine, a potent inhibitor of the presynaptic norepinephrine transporter that plays an important role in modulating the brain systems that control attention and activity. If approved, atomoxetine will be the first nonstimulant therapy available for the treatment of attention-deficit/hyperactivity disorder (ADHD). Originally called tomoxetine, the drug s name was changed to atomoxetine in order to avoid any confusion with tamoxifen, the drug marketed for breast cancer therapy. The safety of atomoxetine was demonstrated in a separate poster presentation. The atomoxetine efficacy analysis presented at the APA annual meeting included data from 2 randomized, double-blind, placebo-controlled studies. One study was a dose-finding trial (placebo and atomoxetine 0.5 mg/d, 1.2 mg/d, and 1.8 mg/d) that utilized a twice-daily dosing regimen (placebo and atomoxetine 1.2 mg/d and 1.8 mg/d were included in the analysis). The second study was a dose-titration trial that utilized a once-daily dose. The study s patient population included children (296) and adolescents (120) who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for ADHD with a baseline severity score measured by ADHD Rating Scale (ADHD RS) at least 1.5 standard deviations above the age and gender norms for their diagnostic subtype. Excluded from the study were children and adolescents with serious medical illness, comorbid psychosis or bipolar disorder, history of seizure disorder, or ongoing use of psychoactive medication other than the study drug. Primary efficacy measure for the study was the ADHD RS-IV Parent Version, with the Conners Parent Rating Scale-Revised Short Form (CPRS-R) and Clinical Global Impressions of Severity (CGI-S) used as secondary efficacy measures. Efficacy was measured by comparing improvement in mean scores from baseline to last observation between atomoxetine and placebo. Statistical comparisons were performed using an analysis of variance including a model with study, treatment, age category (children/adolescents), and treatment-byage category interaction. The figure demonstrates that in the ADHD total score, no significant change in efficacy from baseline was demonstrated between children and adolescents for either atomoxetine (P =.963) or placebo (P =.291). In the component of the ADHD RS relating specifically to inattentiveness, no significant difference was found between children and adolescents for either atomoxetine (P =.942) or placebo (P =.305). Both children and adolescents in the drug treatment group were found to experience a mean change from baseline of approximately -7.0 (P<.001 and P =.012, respectively), as compared with to in the placebo study arm. Similar results were reported for children and adolescents treated with atomoxetine compared with placebo in the Hyperactive/Impulsive Subscale Score (P<.001, P =.024, respectively), CGI-S (P<.001, P =.002, respectively), and the CPRS-R ADHD Index (P<.001, respectively). Significant improvements from baseline for subjects undergoing drug therapy were reported in ADHD RS Total Score (-13.31, children; , adolescents); Inattentive Subscale Score (-7, children; -6.9, adolescents); Hyperactive/Impulsive Subscale 928 Vol. 2, No. 25 November 2002
5 Score (-6.31, children; -6.42, adolescents); and CPRS-R Index Score (-8.42, children; adolescents). Changes from baseline were more modest in the CGI-S subscale (-1.25, children; -1.36, adolescents). In all measures, scores were consistent for both children and adolescents. The data from these 2 clinical trials suggest that atomoxetine is equally efficacious in children and adolescents with ADHD, as measured by significant improvement in the ADHD RS (total and subscale scores), CPRS-R ADHD index, and CGI-S. These studies suggest that atomoxetine will provide an efficacious alternative to psychostimulants in the treatment of child and adolescent ADHD. However, to date, the drug s efficacy has not been directly studied in comparison with psychostimulant therapy. Figure. SUD Outcomes in Stimulant Treated Youths *P<.05. SUD = substance use disorder. LONG-TERM SAFETY OF ATOMOXETINE IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER Based on a poster presentation by Wernicke JF,* Kratochvil C, Milton D,* Dunn D, Spencer T, Heiligenstein J,* and Michelson D* *Eli Lilly and Company; Psychopharmacology Research Center, University of Nebraska Medical Center, Omaha, Nebraska; Indiana University/Riley Hospital, Indianapolis, Indiana; Joint Program in Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts. This study of the long-term safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is among the largest studies of ADHD drug safety to be undertaken, consisting of 325 patients (258 children, 67 adolescents) who were exposed to extended atomoxetine treatment for an average of approximately 78 weeks. The open-label trial enrolled patients aged 7 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for ADHD. The study population had no serious medical illnesses, comorbid psychoses or bipolar disorders, history of seizures, no ongoing use of psychoactive medications other than the study drug, and no history of substance abuse. Although the study is ongoing, the mean number of days on therapy at the time of this interim analysis was 313, with 143 patients completing 1 year of therapy. Among study participants, 3.7% (n = 12) discontinued the study due to an adverse event. Adverse events were rare; those most frequently reported included headache, rhinitis, abdominal pain, pharyngitis, and vomiting. These adverse events, as well as decreased appetite and weight loss sometimes associated with atomoxetine treatment, were reported primarily during initiation of drug therapy, and then tended to decrease significantly over time. Interestingly, this study reported an increase in weight and height among study subjects over time: mean weight increased 2.6 kg and height increased 4.4 cm. The finding is significant, since a source of concern for existing ADHD therapies is appetite suppression and its potential impact on childhood growth. Although atomoxetine is not a stimulant, its use nonetheless resulted in a slight increase in diastolic blood pressure (3.6 mm Hg), systolic blood pressure (3.5 mm Hg), and pulse (3.9 bpm). In addition, a decrease of Advanced Studies in Medicine 929
6 4.8 msec in mean Fridericia-corrected QT interval from baseline to endpoint was observed. This study demonstrates long-term safety of an investigational new class of drug therapy available for the treatment of ADHD, showing atomoxetine to be generally well tolerated. In contrast to acute studies where mean weight loss was observed, this study revealed mean weight increases during long-term therapy. No evidence of a drug-related QTc prolongation was observed. Although adverse events occurred infrequently during the study, those that did occur decreased over time, and new adverse events did not appear later in the treatment of study subjects. According to study author David Michelson, MD, little long-term data has been reported for stimulants to date. These data therefore represent one of the first systemic, prospective studies of the safety of any ADHD medication over an extended period of time. ADHD SUBTYPES CHANGE DRAMATICALLY WITH AGE AND GENDER Based on a poster presentation by Turgay A,* Ansari R, Zafar M, and the Scarborough Hospital ADHD Institute Study Group *University of Toronto, Ontario, Canada; The Scarborough Hospital, Ontario, Canada The Scarborough Hospital attention-deficit/hyperactivity disorder (ADHD) Clinic, Training and Research Institute was established in The institute allowed a large database to be studied by a multidisciplinary team consisting of child, adolescent, and adult psychiatrists with representatives from other medical disciplines as well as social workers and child development specialists. Using the existing database from Scarborough Hospital, researchers investigated the relationships between ADHD, subtypes, age, and gender. The study sample consisted of all patients who were consecutively referred to the Scarborough Hospital ADHD Clinic, Training and Research Institute and who had completed evaluations according to the inclusion criteria between September 1, 1994, and December 31, The Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnostic criteria were used to establish diagnoses for ADHD and comorbid disorders. The study included 2298 male subjects and 635 female subjects (N = 2933) with ADHD who were aged 2 to 68 years; most subjects were in the 6- to 18-year-old age group (n = 2277). Subjects were systematically assessed to determine ADHD subtypes, age, and gender relationships. Evaluations included Gadow-Sprafkin general psychopathology screening scales, DuPaul ADHD scales, and semistructured interviews. Although community-based studies reported 2 decades ago established a 2.5:1 male:female ratio, 1,2 the male:female ratio in this study was 3.6:1 (P<.001), indicating an underidentification of females in the existing literature. As age increased, male:female ratio decreased: Among children aged 2 to 5 years (n = 359), the male:female ratio was 5.18:1; for patients older than 19 years (n = 297), the ratio was very close to the community sample s ratio of 2.5:1. ADHD subtypes changed as age increased. In the 2- to 5-year-old age group, the ratio of ADHD combined type vs ADHD predominantly inattentive type (ADHD:attention-deficit disorder [ADD]) was 38:1. In the group consisting of subjects older than 19 years, the ADHD:ADD ratio was 0:89. ADHD predominantly inattentive type was more common in female than male subjects (30.47% vs18.9%). In every age group, ADHD hyperactive-impulsive type (HI) was the least common subtype, representing 2.08% of male subjects and 1.73% of female subjects. The study conclusions were that ADHD-HI type was rare in every age group studied and in both genders. The proportion of ADHD combined type cases decreased as a function of age, and the percentage of females identified with ADHD increased with age. In this sample, ADHD was underidentified in children younger than 6 years, females, adolescents, adults, and ADHD inattentive type. Community screening with practical, valid, reliable, and sensitive questionnaires is essential. REFERENCES 1. Offord DR, Boyle MH, Racine Y. Ontario Child Health Study: Correlates of disorder. J Am Acad Child Adolesc Psychiatry. 1988;28: Szatmari P, Offord DR, Boyle MH. Ontario child health study: Prevalence of attention deficit disorders with hyperactivity. J Child Psychol Psychiatry. 1989;30: Vol. 2, No. 25 November 2002
Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationScottish Medicines Consortium
Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationAttention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.
ADHD in Preschool Children Preschool ADHD: When Should We Diagnose it & How Should We Treat it? Professor of Pediatrics Diagnosis of ADHD in Preschool Children: Impact of DSM-IV Is Preschool ADHD Associated
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBU
CT Registry ID#7065 Page 1 Summary ID# 7065 Clinical Study Summary: Study B4Z-MC-LYBU A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented with Either Extended-Release Methylphenidate
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationDoes prescribing stimulants to patients with attention-deficit/hyperactivity
Do stimulants for ADHD increase the risk of substance use disorders? For some patients, stimulants might protect against future SUDs Shailesh Jain, MD, MPH, ABDA Regional Chair Associate Professor Department
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationThe shift in nosology from the Diagnostic PROCEEDINGS FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT
FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) tends to manifest differently in adolescents than in children,
More informationORIGINAL INVESTIGATION. Attention-Deficit/Hyperactivity Disorder in Adults. A Survey of Current Practice in Psychiatry and Primary Care
ORIGINAL INVESTIGATION Attention-Deficit/Hyperactivity Disorder in Adults A Survey of Current Practice in Psychiatry and Primary Care Stephen V. Faraone, PhD; Thomas J. Spencer, MD; C. Brendan Montano,
More informationPharmacotherapy of ADHD with Non-Stimulants
Pharmacotherapy of ADHD with Non-Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationPharmacotherapy of ADHD with Non- Stimulants
Pharmacotherapy of ADHD with Non- Stimulants Timothy E. Wilens, M.D. Chief, Division of Child and Adolescent Psychiatry, (Co)Director of Center for Addiction Medicine, Massachusetts General Hospital Massachusetts
More informationATOMOXETINE AND METHYLPHENIDATE TREATMENT IN ADHD
20 ACTA MEDICA MARTINIANA 2015 15/1 DOI: 10.1515/acm-2015-0003 ATOMOXETINE AND METHYLPHENIDATE TREATMENT IN ADHD Snircova E 1,2, Hrtanek I 1,2, Kulhan T 1,2, Nosalova G 1, Ondrejka I. 2 1 Department of
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationComorbidity With Substance Abuse P a g e 1
Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBR
CT Registry ID#6934 Page 1 Summary ID# 6934 Clinical Study Summary: Study B4Z-MC-LYBR Title of Study: A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate
More informationSummary ID# Clinical Study Summary: Study B4Z-SB-LYDD
CT Registry ID# 9496 Page 1 Summary ID# 9496 Clinical Study Summary: Study B4Z-SB-LYDD An Open-label Study on Effectiveness and Tolerability of as Perceived by Patients, Parents, and Physicians in Children
More informationThe relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications
Society for the Study of Addiction, York The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications November 12.th 2010 Soren Dalsgaard, MD, PhD, associate
More informationClonidine extended-release tablets for the treatment of ADHD
Clonidine extended-release tablets for the treatment of ADHD Joan Daughton*, Lindsey Corr, Howard Liu & Madeline West Practice points Stimulant medications remain the first-line treatment for ADHD. Based
More informationSummary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ
CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus
More informationAttention Deficit Hyperactivity Disorder
R E S E A R C H P A P E R Comparative Short term Efficacy and Tolerability of Methylphenidate and Atomoxetine in Attention Deficit Hyperactivity Disorder JASMIN GARG, PRITI ARUN AND BS CHAVAN From Department
More informationFinal Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052
Final Report of Activity February 21 st, 2006 to April 30 th, 2006 CHEO Grant 052 1- Title of Study: The prevalence of neuropsychiatric disorders in children and adolescents on an inpatient treatment unit:
More informationUnderstanding the Use of Psychotherapy and Psychotropic Medications for Oppositional Defiance and Conduct Disorders. Prof.
Understanding the Use of Psychotherapy and Psychotropic Medications for Oppositional Defiance and Conduct s Prof. Daniel Kaplin College of Staten Island One of the new chapters in the Diagnostic and Statistical
More informationAttention Deficit Hyperactivity Disorder Overview and New Perspectives
1st Annual Regional Psychiatry Conference Psychiatry for the Non-Psychiatrist Attention Deficit Hyperactivity Disorder Overview and New Perspectives Thomas B. Henry, MD Board Certified Child & Adolescent
More informationPsychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.
Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBD
CT Registry ID#5286 Page 1 Summary ID# 5286 Clinical Study Summary: Study B4Z-JE-LYBD An Open Label, Dose-Titration Safety Study of Hydrochloride in Outpatient Japanese Children with Attention-Deficit/Hyperactivity
More informationRole of ADHD medication in children with autism spectrum disorder. Pieter Hoekstra University of Groningen, Netherlands
Role of ADHD medication in children with autism spectrum disorder Pieter Hoekstra University of Groningen, Netherlands Symptoms of ADHD are highly prevalent in children with ASD Two independent chart reviews
More informationAttention-deficit/hyperactivity disorder and dissociative disorder among abused children
Blackwell Publishing AsiaMelbourne, AustraliaPCNPsychiatry and Clinical Neurosciences1323-13162006 Folia Publishing Society2006604434438Original ArticleADHD and dissociation in abused childrent. Endo et
More informationPRESCRIBING PHYSICIANS PLEASE READ
PRESCRIBING PHYSICIANS PLEASE READ USADA s mission is to protect the rights of clean athletes. Some athletes need to use stimulants to manage ADD/ADHD and the anti-doping community acknowledges and respects
More informationAbstract and Introduction
Increasingly physicians are using Atomoxetine known as Strattera as the only non-stimulant for the treatment of ADHD. Since ADHD is the most frequently diagnosed psychological disorder in children and
More informationTimothy E. Wilens, M.D. ADHD & Substance Use Disorders
Timothy E. Wilens, M.D. ADHD & Substance Use Disorders Chief, Division of Child & Adolescent Psychiatry; (Co) Director, Center for Addiction Medicine Massachusetts General Hospital Harvard Medical School
More informationPharmacotherapy of Adult ADHD
Pharmacotherapy of Adult ADHD Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Disclosures Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted
More informationPrediction of Placebo Response in 2 Clinical Trials of Lisdexamfetamine Dimesylate for the Treatment of ADHD
Prediction of Placebo Response in 2 Clinical Trials of Lisdexamfetamine Dimesylate for the Treatment of ADHD James G. Waxmonsky, MD; Daniel A. Waschbusch PhD; Stephen J. Glatt, PhD; and Stephen V. Faraone,
More informationReal-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder
ORIGINAL ARTICLE Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder Samaneh Kabul, 1 Carlos Alatorre, 1 Leslie B. Montejano, 2 Amanda M. Farr 2 & David B.
More informationDrug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
More informationAtomoxetine: a novel treatment for child and adult ADHD
EXPERT OPINION Atomoxetine: a novel treatment for child and adult ADHD Marcialee Ledbetter University of Oklahoma-Tulsa, Tulsa, OK, USA Abstract: Attention deficit hyperactivity disorder (ADHD) is a common
More informationBEHAVIOR PROBLEMS AND SUBTYPES OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER WITH COMORBIDITIES
BEHAVIOR PROBLEMS AND SUBTYPES OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER WITH COMORBIDITIES Ruu-Fen Tzang 1,2 and Yue-Cune Chang 3 1 Department of Psychiatry, Mackay Memorial Hospital, 2 Mackay Medicine,
More informationIs ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD
Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric
More informationDifferentiating MDD vs. Bipolar Depression In Youth
Differentiating MDD vs. Bipolar Depression In Youth Mai Uchida, M.D. Staff Physician Clinical and Research Programs in Pediatric Psychopharmacology Massachusetts General Hospital Disclosures Neither I
More informationJeffrey H. Newcorn 1 Peter Nagy. Brian Yan 5 Steven Pliszka
CNS Drugs DOI 10.1007/s40263-017-0468-2 ORIGINAL RESEARCH ARTICLE Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents
More informationChildhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities
Childhood ADHD is a risk factor for some Psychiatric Disorders and co-morbidities By: Dr. Ehsane M. Gad M.B.B.Ch CABMSPsych. D.P.P Post-Fellow Aus. Consultant Child Psychiatry Childhood ADHD and emergence
More informationADHD and Adverse Health Outcomes in Adults
Thomas J. Spencer, MD This work was supported in part by a research grant from Shire (Dr. Spencer) and by the Pediatric Psychopharmacology Council Fund. Disclosures Dr. Spencer receives research support
More informationTitle: ADHD: Symptom Reduction in Follow up Period CMS ID: PP3 NQF #: N/A
Source(s) Office of the National Coordinator for Health Information Technology/Centers for Medicare & Medicaid Services Measure Domain Effective Clinical Care: Outcome Brief Abstract Description Percentage
More informationADHD Part II: Managing Comorbities
ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationPSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE
PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE Introduction and General Principles April 2017 Adapted for New Mexico from with permission from the Texas Department
More informationPrevalence of Attention Deficit/Hyperactivity Disorder (AD/HD) in Primary School Children in Tehran
Tusculum College From the SelectedWorks of university of science & culture 2010 Prevalence of Attention Deficit/Hyperactivity Disorder (AD/HD) in Primary School Children in Tehran Ali shaker Available
More informationWeek 2: Disorders of Childhood
Week 2: Disorders of Childhood What are neurodevelopmental disorders? A group of conditions with onset in the developmental period Disorders of the brain The disorders manifest early in development, often
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationIs Lisdexamfetamine Dimesylate Safe and Effective in Reducing ADHD Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Lisdexamfetamine Dimesylate Safe
More informationFor more than 100 years, extremely hyperactive
8 W H A T W E K N O W AD/HD Predominantly Inattentive Type For more than 100 years, extremely hyperactive children have been recognized as having behavioral problems. In the 1970s, doctors recognized that
More information2. Conduct Disorder encompasses a less serious disregard for societal norms than Oppositional Defiant Disorder.
COURSES ARTICLE - THERAPYTOOLS.US Print Test 1. Conduct Disorder is a psychiatric disorder of childhood and adolescence that is characterized by a persistent disregard for societal norms and rules, as
More informationEur. J. Psychiat. Vol. 27, N. 3, ( ) Keywords: Attention-deficit/hyperactivity disorder; ADHD; Adult; European; Atomoxetine.
Eur. J. Psychiat. Vol. 27, N. 3, (185-205) 2013 Keywords: Attention-deficit/hyperactivity disorder; ADHD; Adult; European; Atomoxetine. Maintenance of Response After Open-Label Treatment with Atomoxetine
More informationDRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
More informationPrevalence of undiagnosed and untreated attention deficit hyperactivity disorder in men with alcohol dependence: a case-control study
DOI: 10.12740/APP/80833 Prevalence of undiagnosed and untreated attention deficit hyperactivity disorder in men with alcohol dependence: a case-control study Sushruth Vinaya Kumar, Sameeran S. Chate, Nanasaheb
More informationADHD Symptomology and Prescription Stimulant Misuse in College Students
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2017 ADHD Symptomology and Prescription Stimulant Misuse in College Students Kelsey
More informationIris Manor, MD. UK Adult ADHD Network 4th Annual Congress London, England September 11, 2014
Metadoxine Extended Release in Adults With Predominantly Inattentive Attention-Deficit/ Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Crossover Trial Disclosures
More informationAtomoxetine in Adults with ADHD: Two Randomized, Placebo-Controlled Studies
in Adults with ADHD: Two Randomized, -Controlled Studies David Michelson, Lenard Adler, Thomas Spencer, Frederick W. Reimherr, Scott A. West, Albert J. Allen, Douglas Kelsey, Joachim Wernicke, Anthony
More informationPerspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
More informationTHE CHALLENGE OF ADHD IN THE PRESCHOOLER
THE CHALLENGE OF ADHD IN THE PRESCHOOLER Paediatric Refresher Course 2011 Vineyard Hotel Prof A. Venter Department of Paediatrics and Child Health University of the Free State Departement Sentrum Department
More informationAnxiety disorders in mothers and their children: prospective longitudinal community study
Anxiety disorders in mothers and their children: prospective longitudinal community study Andrea Schreier, Hans-Ulrich Wittchen, Michael Höfler and Roselind Lieb Summary The relationship between DSM IV
More informationIRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING
FOR IMMEDIATE RELEASE IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING George Town, Cayman Islands January 10, 2019 Ironshore
More informationADHD and Comorbid Conditions A Conceptual Model
ADHD and Comorbid Conditions A Conceptual Model Thomas E. Brown PhD. Assistant Clinical Professor of Psychiatry, Yale University School of Medicine and Associate Director of the Yale Clinic for Attention
More informationThe comparison of behavioral and emotional problems in children with a bipolar parent and children with healthy parents in Zahedan, Iran, 2011
The comparison of behavioral and emotional problems in children with a bipolar parent and children with healthy parents in Zahedan, Iran, 2011 Mahboubeh Firoozkouhi Moghaddam, Nour Mohammad Bakhshani,
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationChild Health Questionnaire (CHQ) Clinical Trials References
Child Health Questionnaire (CHQ) Clinical Trials References Buitelaar JK, Danckaerts M, Gillberg C et al. A prospective, multicenter, open-label assessment of atomoxetine in non-north American children
More informationMore boys than girls with attention deficit hyperactivity
Why More Boys Than Girls With ADHD Receive Treatment: A Study of Dutch Twins Eske M. Derks, 1 James J. Hudziak, 2,3 and Dorret I. Boomsma 1 1 Department of Biological Psychology,Vrije Universiteit,Amsterdam,
More informationBackground. Alain Joseph 1 Rajeev Ayyagari 2 Meng Xie 2 Sean Cai 3 Jipan Xie 3 Michael Huss 4 Vanja Sikirica 5
DOI 10.1007/s00787-017-0962-6 REVIEW Comparative efficacy and safety of attention deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison Alain
More informationAttention deficit hyperactivity disorder (update)
National Institute for Health and Care Excellence Final Attention deficit hyperactivity disorder (update) [I]Withdrawal from pharmacological treatment and drug holidays NICE guideline NG87 Intervention
More informationAcademic Achievement Over 8 Years Among Children Who Met Modified Criteria for Attention-deficit/Hyperactivity Disorder at 4 6 Years of Age
J Abnorm Child Psychol (2008) 36:399 410 DOI 10.1007/s10802-007-9186-4 Academic Achievement Over 8 Years Among Children Who Met Modified Criteria for Attention-deficit/Hyperactivity Disorder at 4 6 Years
More informationTRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Sue Duvall, RN, MPA Associate Director, Drug Regulatory Affairs Pharmaceuticals
More informationADHD Medication and Substance-Related Problems
American Research Journal of Addiction and Rehabilitation Volume 1, Issue 1, 10-15 Pages Research Article Attention-Deficit/Hyperactivity Disorder (ADHD), with aworld-wide prevalence in the general juvenile
More informationAttention-Deficit Hyperactivity Disorder (ADHD) in Adults
Attention-Deficit Hyperactivity Disorder (ADHD) in Adults Key Issues in Mental Health Vol. 176 Series Editors A. Riecher-Rössler Basel M. Steiner Hamilton Attention-Deficit Hyperactivity Disorder (ADHD)
More informationKevin T. Blake, Ph.D., P.L.C. Tucson, Arizona Cross Country Education Brentwood, Tennessee. All Rights Reserved Kevin T. Blake, Ph.D., P.L.C.
Developmentally Disconnected: Evidence-Based Tools for Transforming Social Competence March 2014 Update Kevin T. Blake, Ph.D., P.L.C. Tucson, Arizona Cross Country Education Brentwood, Tennessee 1 Neurobiofeedback
More informationDrug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
More informationA Clinical Translation of the Research Article Titled Antisocial Behavioral Syndromes and. Additional Psychiatric Comorbidity in Posttraumatic Stress
1 A Clinical Translation of the Research Article Titled Antisocial Behavioral Syndromes and Additional Psychiatric Comorbidity in Posttraumatic Stress Disorder among US Adults: Results from Wave 2 of the
More informationnow well characterized as being a prevalent, 1,2 impairing, 3 7 and treatable 8 condition in adults. It has been
Weiss et al Moderators and Mediators of Symptoms and Quality of Life Outcomes in an Open-Label Study of Adults Treated for Attention-Deficit/Hyperactivity Disorder Margaret D. Weiss, MD, PhD; Christopher
More informationSummary ID#2552. Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV)
CT Registry ID# 2552 Page 1 Summary ID#2552 Clinical Study Summary: Study B4Z-MC-LYAF (Final Report, Study Period III Visit Group II Study Period IV) Relapse Prevention after 10-Week and 52-Week Treatment
More informationWonder Girls to Wonder Women: Lessons Learned from a Longitudinal Study of Girls with ADHD
Wonder Girls to Wonder Women: Lessons Learned from a Longitudinal Study of Girls with ADHD Christine Zalecki, Ph.D. Associate Clinical Professor, UC San Francisco Director, Berkeley Girls with ADHD Longitudinal
More informationTreatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Neurotherapeutics DOI 10.1007/s13311-012-0126-9 REVIEW Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder Naomi Ornstein Davis Scott H. Kollins # The American
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationPresented by the National Resource Center on ADHD
Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently
More informationDr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for
Dr S H Jawed Syed.Jawed@dwmh.nhs.uk 01922607039 Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Adult Neurodevelopmental Service, DWMHP NHS Trust Regional
More informationHolistic approach in management of ADHD
Holistic approach in management of ADHD Outline Historic timeline Prevalence ADHD development Treatment modalities Current guidelines for management ADHD Historical Timeline Described in 19 th century
More informationCase Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources
Case Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources Case 3. Risk of Abuse of ADHD Medications Provider: American Pharmacists Association
More informationTITLE: Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder.
Brief Summary TITLE: Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder. SOURCE(S): Practice parameters for the assessment and treatment
More informationUnseen and Stressed? Gender Differences in Parent and Teacher Ratings of ADHD Symptoms and Associations With Perceived Stress in Children With ADHD
658381JADXXX10.1177/1087054716658381Journal of Attention DisordersIsaksson et al. research-article2016 Article Unseen and Stressed? Gender Differences in Parent and Teacher Ratings of ADHD Symptoms and
More informationIs Methylphenidate Transdermal System (Daytrana ) Safe and Effective for Managing Attention Deficit Hyperactivity Disorder Symptoms in Children?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Methylphenidate Transdermal System
More informationCOMORBIDITY PREVALENCE AND TREATMENT OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADHD
COMORBIDITY PREVALENCE AND TREATMENT OUTCOME IN CHILDREN AND ADOLESCENTS WITH ADHD Tine Houmann Senior Consultant Child and Adolescent Mental Health Center, Mental Health Services Capital Region of Denmark
More informationINDEX. P. 2 Provisional List of Potentially Harmful Therapies (Adapted from Lilienfeld, 2007)
Comprehensive List of Currently-Identified Potentially Harmful (PHTs) and Empirically Supported Psychological Treatments (ESTs) for Adults, Adolescents, and Children INDEX P. 2 Provisional List of Potentially
More informationThe Symptom Trajectory of Attention-Deficit Hyperactivity Disorder in Korean School-Age Children
ORIGINAL ARTICLE https://doi.org/10.30773/pi.2017.11.01.1 Print ISSN 1738-3684 / On-line ISSN 1976-3026 OPEN ACCESS The Symptom Trajectory of Attention-Deficit Hyperactivity Disorder in Korean School-Age
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationHow should you use this book?
Preface Attention deficit / hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of attention deficits and/or hyperactivity and impulsivity. Although the emphasis may
More informationCitation for published version (APA): Jónsdóttir, S. (2006). ADHD and its relationship to comorbidity and gender. s.n.
University of Groningen ADHD and its relationship to comorbidity and gender Jónsdóttir, Sólveig IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationAttention-deficit/hyperactivity disorder (ADHD)
A Dose-Response Study of OROS Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder Mark A. Stein, PhD*; Christopher S. Sarampote, PhD ; Irwin D. Waldman, PhD ; Adelaide S. Robb, MD
More informationPHYSICIAN S REFERENCE: TREATMENT & MEDICATIONS RESEARCH: CURRENT CONCEPTS & FUTURE DEVELOMENTS By David W. Goodman, MD
PHYSICIAN S REFERENCE: TREATMENT & MEDICATIONS RESEARCH: CURRENT CONCEPTS & FUTURE DEVELOMENTS By David W. Goodman, MD PHARMACOTHERAPY OF ADULT ATTENTION DEFICIT / HYPERACTIVITY DISORDER Program Overview
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 January 2011 STRATTERA 10 mg, hard capsules B/28 (CIP code: 347 086-4) STRATTERA 18 mg, hard capsules B/28 (CIP
More informationAttention Deficit/Hyperactivity Disorder (ADHD)
Disclaimers Attention Deficit/Hyperactivity Disorder (ADHD) Paul Glasier, Ph.D. Licensed Psychologist I have no relevant financial relationships with the manufacturers(s) of any commercial products(s)
More information